Richard Kuntz - Medtronic PLC President

MDT Stock  USD 87.10  0.18  0.21%   

President

Dr. Richard E. Kuntz, M.D., is an Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of the Company. Prior to that, he was Senior Vice President and President, Neuromodulation from October 2005 to August 2009 and prior to that, he was an interventional cardiologist and Chief of the Division of Clinical Biometrics at Brigham and Womens Hospital and Associate Professor of Medicine and Chief Scientific Officer of the Harvard Clinical Research Institute. since 2015.
Age 63
Tenure 9 years
Professional MarksPh.D
Address 20 On Hatch, Dublin, Ireland, 2
Phone353 1 438 1700
Webhttps://www.medtronic.com

Medtronic PLC Management Efficiency

The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.04 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024
The company has 24.36 B in debt with debt to equity (D/E) ratio of 0.51, which is OK given its current industry classification. Medtronic PLC has a current ratio of 1.72, which is typical for the industry and considered as normal. Debt can assist Medtronic PLC until it has trouble settling it off, either with new capital or with free cash flow. So, Medtronic PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medtronic PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medtronic to invest in growth at high rates of return. When we think about Medtronic PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

John MurabitoCigna Corp
62
Charles LynchMednax Inc
N/A
Everett NevilleCigna Corp
59
CHRISTOPHER HOCEVARCigna Corp
43
Greg AllenCigna Corp
N/A
Dean MirabellaCigna Corp
N/A
Brain EvankoCigna Corp
40
Samuel EbertsLaboratory
57
Edwin DetrickCigna Corp
N/A
Scott FrommerLaboratory
N/A
Kristen LauriaCigna Corp
51
MICHAEL TRIPLETTCigna Corp
59
Matthew MandersCigna Corp
58
Glenn EisenbergLaboratory
63
Stephen AndersonLaboratory
N/A
Kevin SmithMednax Inc
N/A
Matt PerlbergCigna Corp
N/A
Mark BrecherLaboratory
57
Mark BoxerCigna Corp
59
Christopher MBACigna Corp
N/A
William McDowellCigna Corp
N/A
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 95000 people. Medtronic PLC (MDT) is traded on New York Stock Exchange in USA. It is located in 20 On Hatch, Dublin, Ireland, 2 and employs 95,000 people. Medtronic PLC is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Medtronic PLC Leadership Team

Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brett Wall, Executive Vice President and President Restorative Therapies Group
Jennifer Kirk, Chief Accounting Officer, Global Controller
Bradley Lerman, Senior Vice President General Counsel, Corporate secretary
Scott Donnelly, Lead Independent Director
Kenneth Washington, Senior Officer
Richard Anderson, Lead Independent Director
Ryan Weispfenning, Vice President - Investor Relations
Mark Ploof, Senior Services
Sean Lennon, Chief Officer
Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group
Elizabeth Nabel, Independent Director
Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
James Lenehan, Independent Director
John Liddicoat, Executive Vice President and President Americas Region
Shirley Jackson, Independent Director
Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group
Preetha Reddy, Independent Director
Kevin Lofton, Independent Director
Craig Arnold, Independent Director
Robert Pozen, Independent Director
Kendall Powell, Lead Independent Director
Bryan Hanson, Executive VP and Group President of Minimally Invasive Therapies Group
Sally Saba, Chief Inclusion and Diversity Officer
Denise OLeary, Independent Director
Omar Ishrak, Chairman of the Board, Chief Executive Officer
Brad Lerman, Senior Vice President General Counsel, Corporate secretary
Ivan Fong, General VP
Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio
Gary Ellis, CFO and Executive VP
Carol Surface, Chief Human Resource Officer, Senior Vice President
Karen Parkhill, Chief Financial Officer, Executive Vice President
Geoff Martha, Executive Vice President and President - Restorative Therapies Group
Michael Leavitt, Independent Director
Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group
Randall Hogan, Independent Director
Andrea Goldsmith, Independent Director
Robert Hoedt, Executive Vice President and President - EMEA Region
MSc MD, Medical Scientific
Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group

Medtronic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Medtronic PLC Investors Sentiment

The influence of Medtronic PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Medtronic. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Medtronic PLC's public news can be used to forecast risks associated with an investment in Medtronic. The trend in average sentiment can be used to explain how an investor holding Medtronic can time the market purely based on public headlines and social activities around Medtronic PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Medtronic PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Medtronic PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Medtronic PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Medtronic PLC.

Medtronic PLC Implied Volatility

    
  28.21  
Medtronic PLC's implied volatility exposes the market's sentiment of Medtronic PLC stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Medtronic PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Medtronic PLC stock will not fluctuate a lot when Medtronic PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medtronic PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medtronic PLC's short interest history, or implied volatility extrapolated from Medtronic PLC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Medtronic PLC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Medtronic Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Medtronic Plc Stock. Highlighted below are key reports to facilitate an investment decision about Medtronic Plc Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.
Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Medtronic Stock analysis

When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.078
Dividend Share
2.75
Earnings Share
3.15
Revenue Per Share
24.298
Quarterly Revenue Growth
0.047
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.